Azithromycin in one week quadruple therapy for H pylori eradication in Iran

Shahrokh Mousavi, Jafar Toussy, Siamak Yaghmaie, Mehrdad Zahmatkesh

Abstract

AIM: To investigate eradication rates, patient compliance and tolerability of a 1-wk Azithromycin-based quadruple therapy versus the 2-wk conventional therapy.

METHODS: A total of 129 H pylori-positive patients were randomized to either omeprazole 20 mg, bismuth subcitrate 240 mg, azithromycin 250 mg, and metronidazole 500 mg all twice daily for 1-wk (B-OAzM) or omeprazole 20 mg, bismuth subcitrate 240 mg, amoxicillin 1g, and metronidazole 500 mg all twice daily for 2-wk (B-OAM). H pylori infection was defined at entry by histology and rapid urease test and cure of infection was determined by negative urea breath test.

RESULTS: H pylori eradication rates produced by B-OAzM and B-OAM were 74.1% and 70.4% respectively based on an intention to treat analysis, and 78.1% versus 75.7% respectively based on a per-protocol analysis. The incidence of poor compliance was lower, although not significantly so, in patients randomized to B-OAzM than for B-OAM (3.5% versus 4.3%) but intolerability was similar in the two groups (35% versus 33.3%).

CONCLUSION: 1-wk azithromycin based quadruple regimen achieves an H pylori eradication rate comparable to that of standard 2-wk quadruple therapy, and is associated with comparable patient compliance and complications.

© 2006 The WJG Press. All rights reserved.

Key words: Peptic ulcer; Treatment; Azithromycin; H pylori; Non-ulcer dyspepsia

Mousavi S, Toussy J, Yaghmaie S, Zahmatkesh M. Azithromycin in one week quadruple therapy for H pylori eradication in Iran. World J Gastroenterol 2006; 12(28): 4553-4556

http://www.wjgnet.com/1007-9327/12/4553.asp

INTRODUCTION

H pylori is a common human pathogen that has been shown to be a major factor in peptic ulcer disease. It has also been linked to gastric adenocarcinoma and gastric lymphoma[1].

A number of antimicrobial agents have been used in various regimens to eradicate H pylori. Clinical trials are regularly undertaken to search for simpler but equally effective regimens[2-4]. Azithromycin, a new generation macrolide, has some special attributes that suggest it would be a promising compound to be used in regimens for H pylori eradication. It is acid-stable, has a long half-life and achieves remarkably high concentration in the gastric tissue[3,4]. There have been several clinical trials of azithromycin for the therapy of H pylori infection[3,4,5,6,7]. As the pharmacological properties of azithromycin make it possible to use shorter courses, the problem has been to define an optimal dose and duration of azithromycin treatment in the course of therapy[3,4]. On the other hand, in developed countries, regimens of one week’s duration are recommended for H pylori eradication[3,4] but in developing countries 1-wk regimens failed to eradicate the microbe. A minimum of 10 to 14 d of treatment were needed for eradication of the microbe, even in the presence of a favorable sensitivity profile[5,6,7]. The aim of this study was to assess the efficacy of azithromycin in a 1-wk regimen compared with a conventional 2-wk regimen in Iran, so we compared two quadruple regimens; bismuth subcitrate, omeprazole, azithromycin, and metronidazole, for 1-wk (B-OAzM) and bismuth subcitrate, omeprazole, amoxicillin and metronidazole, for 2-wk (B-OAM) in H pylori eradication. The safety and tolerability of the two drugs combinations were also evaluated and compared.

MATERIALS AND METHODS

Patients considered for the study included individuals 18-80 years old with upper GI symptoms that were referred to our gastroenterology clinic for upper endoscopy. Patients with H pylori infection were included in the study. Other inclusion criteria included indication for treatment as per the National Institutes of Health (NIH)
The cessation of therapy. Subjects recorded any side effects. Repeat examination was performed 1 wk and 4-8 wk after continued on omeprazole (20 mg/d) for a total of 1 mo.

One group received a regimen of bismuth subcitrate 240 mg, omeprazole 20 mg, azithromycin (Azithromycin TC®, Tehran shimi, Iran) 250 mg and metronidazole 500 mg, another 75.67% CI0.95: 58.8%-88.22%); the difference was statistically significant (P<0.001). In patients with peptic ulcer, H pylori infection was eradicated in 19 of 25 patients in the B-OAzM group (76%, CI0.95: 75.67%-90.64%) and in 28 of 37 in the B-OAM group (75.75%, CI0.95: 63.63%-85.46%); the difference was not statistically significant (P=0.1, \( \chi^2 \)).

The ITT analysis for eradication was defined before the study to include all subjects who were randomized and received at least one dose of medication. The PP analysis for eradication included all subjects who took at least 80% of each study medication as prescribed.

The comparison of efficacy was evaluated using the \( \chi^2 \) test. The analysis was performed using the SPSS 11.5 statistical package (SPSS, Chicago, IL).

RESULTS

The two groups were comparable in terms of common clinical variables that are summarized in Table 1. Three patients were lost to follow up (two from the B-OAM regimen and one subject from the B-OAzM regimen); also five patients discontinued the drugs because of severe side effects (three from the B-OAM regimen and two subject from the B-OAzM regimen). The remaining 121 patients completed the study as planned.

PP analysis: H pylori infection was eradicated in 43 of 55 patients in the B-OAzM group (78.18%, CI0.95: 64.98%-88.18%) and in 50 of 66 patients in the B-OAM group (75.75%, CI0.95: 63.63%-85.46%); the difference was not statistically significant (\( \chi^2 = 0.1, P = 0.75 \)).

In patients with peptic ulcer, H pylori infection was eradicated in 19 of 25 patients in the B-OAzM group (76%, CI0.95: 75.67%-90.64%) and in 28 of 37 in the B-OAM group (75.67%, CI0.95: 58.8%-88.22%); the difference was not statistically significant (\( \chi^2 < 0.001, P = 0.97 \)).

Complications: the overall results for side effects are summarized in Table 2. Complications were noted in 14 patients in the B-OAzM group (25.45%) and 17 patients in the B-OAM group (25.75%) with no statistically significant differences between the groups (\( \chi^2 < 0.001, P = 0.96 \)). The symptoms were mild and did not necessitate any additional treatment except in the five patients that discontinued the drugs for severe complications.

DISCUSSION

Although various regimens have been recommended for H pylori eradication, all of them include at least 2 antibiotics and one acid inhibitory drug[11]. In western countries,

---

**Table 1 Clinical and demographic data of patients in the treatment groups**

| Data                  | B-OAM-2 wk regimen n (% | B-OAzM-1 wk regimen n (%) | P value¹ |
|-----------------------|-------------------------|---------------------------|----------|
|ITT analysis           | 71                      | 58                        |          |
|Age yr, Mean (SD)      | 48.3 (7.4)              | 46.7 (8.4)                | 0.17     |
|Male                   | 45 (63.3)               | 33 (56.8)                 | 0.45     |
|NSAID users            | 21 (29.5)               | 15 (25.8)                 | 0.63     |
|Cigarette smokers      | 11 (15.4)               | 8 (13.7)                  | 0.78     |
|Abdominal pain         | 47 (66.1)               | 31 (53.4)                 | 0.14     |
|Heartburn              | 14 (19.7)               | 18 (31)                   | 0.13     |
|Dyspepsia              | 57 (80.2)               | 40 (68.9)                 | 0.13     |
|PU                     | 37 (52.1)               | 25 (43.1)                 | 0.3      |
|Non-ulcer dyspepsia    | 34 (47.8)               | 33 (56.8)                 | 0.3      |
|Loss to follow up      | 2                       | 1                         |          |
|Poor compliance        | 3                       | 2                         |          |
|Drop-outs              | 5                       | 3                         |          |
|PP analysis            | 66                      | 55                        |          |

¹ for means and \( \chi^2 \) for proportions, ITT; intention to treat, PP; per protocol.

---

Consensus Conference including: peptic ulcer disease, history of peptic ulcer, chronic gastritis, gastric mucosa-associated lymphoid tissue, or intestinal metaplasia[1,7]. Between October 2003 and October 2004, a total of 129 patients were enrolled in the study. All patients gave written informed consent before entering the study and the protocol was reviewed and approved by the Semnan Gastrointestinal and Liver diseases Research Center. The criteria for exclusion were: intake of proton pump inhibitors, antibiotic or bismuth salts within 4 wk prior to the study, stomach surgery, known hypersensitivity to one of the study medications, patients with liver cirrhosis, renal failure or other serious comitant illness, pregnant women, and patients who had previously undergone eradication therapy. These criteria were ascertained by taking a complete history, physical examination, and appropriate hematological and biochemical tests. The demographic and endoscopic data of these patients are reported in Table 1.

On initial endoscopy, H pylori infection was determined by rapid urease test and histological assessment. Rapid urease test was performed using two biopsy specimens; one from the antrum and the other from the corpus[11]. Histological assessment of H pylori status was performed using one further biopsy specimen from the antrum; within 3 cm of the pylorus (hematoxylin-eosin and Giemsa stains)[12,13]. The patients were considered to be infected if both the urease test and histology were positive on initial testing. These criteria were ascertained by taking a complete history, physical examination, and appropriate hematological and biochemical tests. The demographic and endoscopic data of these patients are reported in Table 1.
the most effective and usual regimens for preliminary treatment include; triple regimens for at least 1 wk, and use of clarithromycin as the antibiotic of choice against *H pylori*. Metronidazole, on the other hand, has largely been eliminated from first-line *H pylori* therapy because of its intolerability and high drug resistance\[14\]. However, in developing countries, effective treatments for *H pylori* vary from those used in developed countries. For example in middle east countries it has been shown that one week regimens fail to eradicate the microbe and the course of treatment should be continued for at least 10-14 d to provide for eradication\[8-10\]. Further, clarithromycin is not appropriate use because of its high price, drug resistance and unavailability\[15,16\] and so metronidazole is a common and effective drug in *H pylori* treatment in this setting.

Although the prevalence of *H pylori* strains that are resistant to metronidazole varies from 46%-51% in Iran\[2,4,6,7\], it has been shown that this drug in high doses (> 1 g) and in combination with other drugs remains effective against *H pylori*\[13,14\]. Therefore, in Iran as also done in some Asian countries\[4,19\], metronidazole is a very common drug used in *H pylori* eradication regimens\[20\]. In Iran, the most common regimens for first-line treatment are 2-wk quadruple regimens that include; metronidazole, omeprazole, bismuth and tetracycline or amoxicillin\[14\]. This conventional regimen introduced initially by Hosking, Deboer, Borody, and Laine as an effective regimen in *H pylori* treatment has confirmed efficiency of a 63%-93% eradication rate\[17,23\]. On other hand, due to high rates of resistance to metronidazole, furazolidone was used instead of it, as first or particularly second line treatment\[24\].

Although 2 wk regimens have been effective in *H pylori* eradication, some patients withdraw from their treatment because of the long duration and large number of tablets. Thus, in this study we showed that a quadruple regimen, where azithromycin replaced amoxicillin, the duration of the treatment can be decreased without any change in its effectiveness. Azithromycin is a new macrolide related to clarithromycin with an effective role in *H pylori* eradication and it was reported that azithromycin has a synergic effect withesomeprazole, even in presence of drug resistance\[26\]. In various studies the effectiveness of azithromycin has been evaluated in different doses from 500 mg to 3 g\[13,27,29\], although in most studies this drug was used for 3 d (1.5 g) as in respiratory tract infection but at this dose it has less effect than clarithromycin\[15,26\]. However, by increasing the total dose to 3 g, it has been shown that the effectiveness of azithromycin can be restored\[14,16,27\].

This is the first study in which azithromycin was used at a prescribed amount of 3.5 g (250 mg bid for 7d) in the treatment of *H pylori* infection. Fortunately, the patients’ tolerance was excellent. There were a few side effects based on biochemical tests, but most side effects were mild and disappeared with conservative therapy without the need to terminate the treatment.

Finally, in areas where clarithromycin cannot be used because of drug resistance or unavailability, azithromycin with a total dose of 3.5 g is an appropriate and safe drug for *H pylori* eradication regimen.

The effectiveness of furazolidone based *triple or quadruple regimens* has been evaluated in Iran\[3,4,6,7\], but because of resistance to metronidazole, it seems possible that a combination of azithromycin and furazolidone instead of azithromycin and metronidazole will achieve more favorable eradication rates, although further evaluation is needed.

### Table 2 Complications of drugs in *H pylori* treatment

| Complication | B-OAM-2 wk regime | B-OaM-1 wk regime | P value\[A\] |
|--------------|-------------------|------------------|--------------|
| n            | 69\[B\]           | 57\[B\]          |              |
| Diarrhea (%) | 4 (5.7)           | 4 (7)            |              |
| Vomiting (%) | 5 (7.2)\[C\]      | 4 (7)            |              |
| Abdominal pain (%) | 7 (10.1)          | 5 (8.7)          |              |
| Bad taste (%) | 7 (10.1)          | 5 (8.7)          |              |
| Anal pain (%) | 0                 | 2 (3.5)          |              |
| Total (%)    | 23 (33.3%)        | 20 (35%)        | 0.83         |

\[A\] Three patients of group ‘A’ and two patients of group ‘B’ excluded from the study for severe vomiting; \[B\]\[C\] All patients except lost to follow up cases.

### REFERENCES

1. Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; 16: 167-180
2. Sullivan B, Coyle W, Nemeć R, Zunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. *Am J Gastroenterol* 2002; 97: 2536-2539
3. Blandizzi C, Malizia T, Gherardelli G, Costa F, Marchi S, Marvaggi G, Natale G, Senesi S, Bellini M, Maltinti G, Campa M, Taccia MD. Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. *J Antimicrob Chemother* 1998; 42: 75-82
4. Ivashkin VT, Lapina TL, Bondarenko OY, Sklanskaya OA, Grigoriev PV, Varfeyev YY, Yakovenko EP, Gulyaev PV, Fedchenko VI. Azithromycin in a triple therapy for *H pylori* eradication in active duodenal ulcer. *World J Gastroenterol* 2002; 8: 879-882
5. Silva FM, Eising JN, Chehter EZ, da Silva JJ, Laudanna AA. Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer. *Rev Hosp Clin Fac Med Sao Paulo* 2002; 97: 9-14
6. Krichhoff RM, Lauen H, Schacke G, Kirchhoff G, Gallo E. Determination of azithromycin in gastric biopsy samples. *Int J Clin Pharmacol Ther* 1999; 37: 361-364
7. Peitz U, Menegatti M, Vaira D, Malfertheiner P. The European meeting on Helicobacter pylori: therapeutic news from Lisbon. *Gut* 1998; 43 Suppl 1: S66-69
8. Malekzadeh R, Merat S, Derakhsh MH, Siavoshy F, Yazdanbod A, Mikael J, Sotoudehmanesh R, Sotoudeh M, Farahvash MJ, Nasser-Moghadam S, Purshams A, Dolatshahi S, Abedi B, Babaei M, Arshi S, Majidpour A. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. *J Gastroenterol Hepatol* 2003; 18: 13-17
9. Gumurduy Y, Serin E, Ozber K, Kayaselek F, Oszahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacoglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. *World J Gastroenterol* 2004; 10: 668-671
and its impact on treatment options. Eur J Gastroenterol Hepatol 1999; 11: 709-712

21 Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999; 12: 19-26

22 Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 2001; 64: 222-225

23 Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567

24 Altintas E, Ulu O, Sezgin O, Aydin O, Camdeviren H. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy. Turk J Gastroenterol 2004; 15: 90-93

25 Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-416

26 Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarrat S. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303

27 Iacopini F, Crispino P, Paoluzzi OA, Consolazio A, Pica R, Rivera M, Palladini D, Nardi F, Paoluzzi P. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005; 37: 571-576

28 Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. Am J Gastroenterol 1999; 94: 962-966

29 Anagnostopoulos GK, Kostopoulos P, Margaritis G, Tsikas S, Arvanitidis D. Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection. J Clin Gastroenterol 2003; 36: 325-328

S-Editor Wang J L-Editor Barrett KE E-Editor Bi L